Please assess the completion status of the following clinical trial:

Trial Title: Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Have active RA as shown by five or more swollen joints (from the 66-joint count), five or more tender joints (from 68-joint count), and a serum CRP ≥1.0 mg/dL;~* Have received methotrexate for 12 weeks or longer and at a stable dose of 7.5 to 25 mg/week for at least 4 weeks prior to screening and willing to continue on this regimen for the duration of the study;~* If taking oral steroids, these should be at a dose ≤10 mg/day of prednisone or prednisone equivalent and stable for at least 4 weeks prior to screening;~* If taking non-steroidal anti-inflammatory drugs (NSAIDs), these must be at a stable dose for at least 2 weeks prior to screening;~* Female subjects must have a negative pregnancy test unless they are surgically sterile or have been post-menopausal for at least one year;~* Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for at least 12 weeks after the last dose of study drug.~* Sexually active men must agree to use a medically acceptable form of contraception during the study and continue its use for at least 3 months after the last dose of study drug; and~* Able and willing to sign the informed consent prior to screening evaluations and agree to schedule of assessments.~Exclusion Criteria:~* Treatment with disease-modifying antirheumatic drugs (DMARDs), other than background methotrexate;~* Current or previous RA treatment with a biological agent, with the exception of biologics administered in a clinical study setting more than six months prior to screening (12 months for rituximab or other B cell depleting agents);~* Previous treatment at any time with a cytotoxic agent, other than methotrexate, before screening;~* Previous use of the study drug GLPG0634;~* Receipt of an intra-articular or parenteral corticosteroid injection within 4 weeks prior to screening;~* Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the Investigator;~* Positive serology for HIV1 or 2 or hepatitis B or C, or any history of hepatitis from any cause with the exception of hepatitis A;~* History of any inflammatory rheumatological disorders other than RA;~* History of tuberculosis (TB) infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- capsule, 30mg GLPG0634 once a day (Type: EXPERIMENTAL): 3 capsules of 10 mg once a day
- capsules, 75mg GLPG0634 once a day (Type: EXPERIMENTAL): 3 capsules of 25mg once a day
- capsules, 150mg GLPG0634 once a day (Type: EXPERIMENTAL): 3 capsules of 50mg once a day
- capsules, 300mg GLPG0634 once a day (Type: EXPERIMENTAL): 3 capsules of 100mg once a day
- capsules, placebo once a day (Type: PLACEBO_COMPARATOR): 3 capsules placebo once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete